Evaluation of the Clinical Efficacy of Moxibustion With Regulating Yin and Yang in the Treatment of Menopausal Obesity

Not Applicable

• Conditions: Obesity

• Registration Number: NCT04943705
• Lead Sponsor: Hubei Hospital of Traditional Chinese Medicine

Brief Summary

This study is designed as a two-dummy randomized controlled trial to evaluate the safety and superiority of Yin and Yang regulating moxibustion in the treatment of menopausal obese patients.

Detailed Description

The study will be a multicenter, randomized, controlled trial, conducted from January 2021 to December 2022, including 216 menopausal obese patients who meet the inclusion criteria. The subjects will be randomly divided into 2 treatment groups: Yin and Yang regulating moxibustion group and mild moxibustion group. Each group of treatment will last for 12 weeks, with a follow-up period of 12 weeks. The main outcome indicator is waist circumference. The secondary outcome indicators include subjects related to obesity, TCM clinical syndrome score and modified Kupperman score, weight impact on quality of life scale (IWQOL-Lite), quality of life assessment health survey summary (SF-36). During the intervention period, adverse events will be recorded.

Study Timeline

• Status Verified: 2021-06
• Study First Submitted: 2021-06-13
• Study First Submitted QC: 2021-06-27
• Last Update Submitted: 2021-06-27
• Study First Posted: 2021-06-29
• Last Update Posted: 2021-06-29
• Study Start: 2021-07-01
• Primary Completion: 2021-12-30
• Study Completion: 2022-12-30

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Female
• Target Recruitment: 216

Inclusion Criteria

1. Patients who meet the diagnostic criteria for menopausal syndrome and obesity;
2. Patients with BMI≥25 and waist circumference≥80cm;
3. Female patients between 40-60 years old;
4. Have not taken any hormone drugs or weight loss related drugs in the past 3 months;
5. Sign the informed consent and voluntarily accept the intervention methods of this project.

Exclusion Criteria

1. Unexplained vaginal bleeding, or unnatural menopause;
2. Have used hormone replacement therapy or other drugs related to this disease in the past 3 months;
3. Combined with serious organic diseases, endocrine diseases, heart, liver and kidney, and respiratory diseases;
4. Secondary obesity caused by hypothalamic lesions, hypothyroidism, glucocorticoid therapy, etc.;
5. Combined with organic uterine diseases, such as polycystic ovary syndrome, malignant tumors, severe cervical erosion, after total hysterectomy, etc.;
6. There are contraindications to moxibustion, such as moxibustion intolerance, skin allergies, scars, and other serious skin diseases;
7. Poor compliance and unable to adhere to treatment.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Waist circumference	Week 0, 4, 8, 12, 18and24.	The change in waist circumference compared to the baseline.

Secondary Outcome Measures

Name	Time	Method
Body fat percentage(F percent)	Week 0, 4, 8, 12, 18and24.	Body fat percentage(F percent) will be measured.
Waist-to-hip ratio(waist circumference/hip circumference)	Week 0, 4, 8, 12, 18and24.	Waist-to-hip ratio(waist circumference/hip circumference) will be measured.
Modified Kupperman score	Week 0, 12and24.	The modified KMI score scale was used to evaluate the clinical symptoms of menopause before and after treatment.The minimum value is 0#the maximum value is 63. The lower the total score, the lighter the clinical symptoms of the patient.
Blood lipids: cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL-C), high-density lipoprotein (HDL-C).	Week 0 and 12.	Compared with the baseline, the change value of this indicator.
Estrogen: estradiol (E2), serum follicle-forming hormone (FSH).	Week 0 and12.	Compared with the baseline, the change value of this indicator.
BMI(weight/height²)	Week 0, 4, 8, 12, 18and24.	BMI (weight/height²) will be measured.
Weight(WG)	Week 0, 4, 8, 12, 18and24.	Weight(WG) will be measured.
The impact of weight on quality of life (IWQOL)-Lite scale	Week 0, 12and24.	The impact of weight on quality of life (IWQOL)- Lite scale will be measured. The minimum value is 31#the maximum value is 155. The lower the total score, the lighter the clinical symptoms of the patient.
The MOS Item Short from Health Survey（SF-36).	Week 0, 12and24.	This scale is a universal health-related quality of life scale. The minimum value is 40#the maximum value is 147.The higher the comprehensive score, the better the quality of life.
Hip circumference(HC)	Week 0, 4, 8, 12, 18and24.	Hip circumference(HC) will be measured.
The syndrome score of Traditional Chinese Medicine	Week 0, 12and24.	The syndrome score of Traditional Chinese Medicine will be adopted as the criterion of syndrome determination according to the diagnostic and therapeutic evaluation standard of simple obesity revised by the 5th National Obesity Research Conference in 1997. The minimum value is 0#the maximum value is 30. The lower the total score, the better of the outcome.

Trial Locations

Locations (2)

Hubei Provincial Hospital of Traditional Chinese Medicine; 🇨🇳 Wuhan, Hubei, China

Zhong-Yu Zhou; 🇨🇳 Hubei, China